Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	50.67B
Revenue (ttm)	11.01B
Net Income (ttm)	185.18M
Shares Out	300.00M
EPS (ttm)	n/a
PE Ratio	273.63
Forward PE	n/a
Dividend	1.11 (0.65%)
Ex-Dividend Date	Aug 12, 2025

Volume	1,580,301
Average Volume	3,160,764
Open	172.20
Previous Close	172.00
Day's Range	165.00 - 174.30
52-Week Range	79.95 - 216.00
Beta	1.06
RSI	40.48
Earnings Date	Aug 14, 2025

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 619
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2024, IST:GENIL's revenue was 14.74 billion, an increase of 25.25% compared to the previous year's 11.77 billion. Earnings were 148.68 million, a decrease of -77.35%.